NCCN Recommends Zanubrutinib as First-Line, Se... - CLL Support
NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL, SLL
You need to be a member of this community to see this post.
36 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
NCCN adds AV and AVO as Preferred Regimens
In February of this year (2025), the NCCN added AV (Acalabrutinib/Calquence plus Venetoclax) and...
Zanubrutinib-Gazyva Shows Promise for CLL/SLL
June 25, 2019
Zanubrutinib (BGB-3111) is an investigational small molecule inhibitor of Bruton’s...
Zanubrutinib looks promising on all fronts in first interim analysis of ALPINE Trial - Ibrutinib v Zanubrutinib in R/R CLL - report from EHA
Dr Pete Hillmen (UK) reported on this at EHA on 11th June 2021
Background
First-generation BTK...
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
Optimal Treatment Combinations in the Management of CLL/SLL Jeff Sharman, MD Provided by Clinical Care Options, LLC
Optimal Treatment Combinations in the Management of CLL/SLL Jeff Sharman, MD
An installment...
Related Posts
- Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
Consensus recommendations for CLL/SLL treatment selection and sequencing in the US- Advances in Targeted Therapy for R/R CLL OncLive videos & transcripts by Nirav Shah MD & Nicole Lamanna MD
- Efficacy and safety of new‑generation BTKis (primarily acalabrutinib and zanubrutinib) in CLL/SLL: a systematic review and meta‑analysis
- BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'
